Introduction DeNovaMed, Inc. is a company that specializes in creating antibiotics to combat infections caused by drug-resistant bacteria, also known as superbugs. Their primary focus is on treating Gram-positive infections, including those caused by methicillin-resistant Staph and vancomycin-resistant Enterococcus. These infections pose a significant risk to patients in healthcare settings, such as hospitals and community health facilities, as they can lead to skin, wound, and systemic infections. Additionally, the company has an ongoing research program for Gram-negative adjuvants, which have the potential to enhance the effectiveness of older antibacterial treatments. DeNovaMed, Inc. was established in 2006 by Donald F. Weaver, Christopher R. McMaster, and David Byers, and is headquartered in Halifax, Canada. |